# CDIB BioScience Ventures

> CDIB BioScience Ventures is a VC fund in San Diego backing Biotechnology and Medical. See 17 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: San Diego, United States
- Total investments: 17
- Last investment: Jul 2008
- Lead investor: 12%
- Last updated: Aug 2026
- Website: http://www.cdibbiosciencevc.com
- Facebook: https://www.facebook.com/yongshengdalishishicaigongchengjingpinzhizuo

CDIB BioScience Ventures is a VC fund in San Diego focused on Biotechnology and Medical. CDIB BioScience Venture Management (CBVM) is a life science venture management company with operations in US and Taiwan. The majority of management team was spun-off from CDIB (China Development Industrial Bank) in 2001, one of the largest investment banks in Asia. CDIB remains to be a minor investor to the fund. The team has invested over 50biotech companies globally in the past 10 years and majority of them successfully listed in global stock market exchanges or acquired.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 9 | 53% |
| Medical | 7 | 41% |
| Pharmaceutical | 7 | 41% |
| Health Care | 6 | 35% |
| Therapeutics | 4 | 24% |

21 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 5 | 29% |
| Series A | 3 | 18% |
| Series B | 3 | 18% |
| Series D | 2 | 12% |
| Funding Round | 2 | 12% |

6 stages tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| ConforMIS | Conformis is a medical technology company that uses its proprietary iFit® Image-to-Implant® technology platform to develop, manufacture, and sell joint replacement implants and instruments that are individually sized and shaped, which it refers to as personalized, individualized, or sometimes as customized, to fit each patient’s unique anatomy.Conformis offers a broad line of sterile, personalized knee and hip implants and single-use instruments delivered to hospitals and ambulatory surgical centers. | $14.9M | Series D | Jul 09, 2008 |  |
| Ocera Therapeutics | Ocera is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for patients with acute and chronic liver disease, an area of high unmet medical need.Ocera's HE clinical development efforts include a recently completed Phase 2b clinical trial, STOP-HE, which evaluated the safety andefficacy of intravenously-administered OCR-002 in resolving neurocognitive symptoms of acute HE in hospitalized patients with elevated ammonia. Ocera is preparing to meet with the FDA later this year to review the IV program and discuss potential development paths forward. | $35.5M | Series C | Feb 20, 2008 |  |
| Epiphany | Epiphany Biosciences is developing both therapeutic products and diagnostic technologies that treat or prevent the spread of pathogenic viruses.Epiphany Biosciences is a privately-held company located in San Francisco, CA. To support its mission, Epiphany has assembled a world-class team of virologists, clinicians, and drug development expertswith extensive pharmaceutical business experience to lead the company forward. | $36M | Series A | Mar 16, 2007 |  |
| Proprius Pharmaceuticals | Proprius Pharmaceuticals is a San Diego-based drug developer focused on rheumatology and autoimmune diseases. The company offers two early clinical-stage therapeutic candidates comprising a product to treat pain and a product to treat rheumatoid arthritis. Proprius Pharmaceuticals was founded in 2005. | $11M | Series A | Jan 08, 2007 |  |
| Aprima Medical Software | Aprima is dedicated to easing the transition for physicians moving from either a paper-based environment, or another EHR, to one where information technology makes it easier to practice medicine and run your business. Since 1998, they’ve helped thousands of doctors improve quality of care, patient satisfaction, the bottom line, and their ownquality of life.Their EHR, Practice Management, and Revenue Cycle Management solutions are designed to complement and simplify your workflow, not hinder it. Aprima customers were among the first in the nation to receive Meaningful Use dollars, and they’re continuing to refine their solutions to make practicing medicine easier, faster and more rewarding.They serve physicians nationwide, in primary care and more than 30 specialties, from solo practitioners to large, multi-site clinics. Clients benefit from their vast experience in healthcare IT, the long-term vision of their leadership, their advanced technology that physicians use to optimize their practice, and their U.S.-based client support. Their success depends on your success, and virtually all physicians that have become Aprima users in the past 15 years remain satisfied users today.Based in Carrollton, TX, Aprima performs all development, implementation and support from the U.S. They’re dedicated to the physician market and one of the fastest growing companies in all of north Texas, as well as the EHR market in general. Their steady growth is also enabling us to make investments that benefit their customers, such as ongoing product development to not only meet, but exceed, the requirements for Stages 2 & 3 of Meaningful Use, ICD-10, PQRS, and their acquisition of the Health Care Strategies in 2011.Save time, improve patient care, and get paid promptly. Aprima makes practicing medicine a better experience for clinicians, patients, and staff. Let’s talk about how they can make it work for you. | $6.8M | Series C | Dec 28, 2006 |  |
| Xanthus Pharmaceuticals | Xanthus Pharmaceuticals Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, acquisition, and commercialization of small-molecule therapeutics for the treatment of cancer and autoimmune disorders. | $25M | Series B | Dec 01, 2006 |  |
| Elixir Pharmaceuticals | Elixir Pharmaceuticals is a pharmaceutical company focused on the discovery, development and commercialization of novel pharmaceuticals for the treatment of metabolic diseases such as diabetes and obesity. The Company's scientific founders identified that interactions between specific genes and enzymes can slow the aging process, and they aredeveloping compounds that stimulate these interactions and will be used to treat a range of diseases of aging, including metabolic disease. | $31M | Series C | Nov 27, 2006 |  |
| Nanosys | Nanosys, Inc. researches, develops, and manufactures light-emitting Quantum Dot (QD) technologies for use in a wide range of applications from displays to agriculture. Quantum dots are nanoscale semiconductors that enable displays to reproduce a more lifelike image with a wider range of color and higher brightness. Quantum Dot technologies arecompatible with and offer improved performance for displays of all types including LED-LCDs, OLEDs, and micro-LEDs. As of 2020, consumer electronics brands have shipped more than 20 million devices across over 400 unique products including televisions, monitors, tablets, and automotive interiors based on Nanosys’ proprietary quantum dot technology. | $41.5M | Series C | Nov 09, 2005 |  |
| Cerexa Inc. | Cerexa is a biopharmaceutical company focused on the development of a portfolio of novel anti-infective therapies for the treatment of serious and life-threatening infections. The company’s product portfolio includes Ceftaroline AcetateCeftaroline, an injectable cephalosporin that is used for the treatment of bacterial infections caused bygram-positive and gram-negative pathogens. | $50M | Series A | Aug 23, 2005 |  |
| Somaxon Pharmaceuticals | Somaxon Pharmaceuticals is a growing specialty pharmaceutical company dedicated to commercializing proprietary branded prescription therapeutics to treat important medical conditions where there is an unmet medical need and/or high-level of patient dissatisfaction. The company currently is focusing on in-licensing, developing and marketingproprietary products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area.Somaxon currently is promoting Silenor®, the first and only nonscheduled prescription medication approved for the treatment of sleep maintenance insomnia. Silenor is now available for prescription in the United States. | $65M | Series C | Jun 06, 2005 |  |

10 of 17 investments shown.

## Co-investors
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 3 deals together
- [Domain Associates](https://shizune.co/investors/profile/domain-associates) — VC Fund, 3 deals together
- [Montreux Equity Partners](https://shizune.co/investors/profile/montreaux-equity-partners) — VC Fund, 3 deals together
- [MPM Capital](https://shizune.co/investors/profile/mpm-capital) — VC Fund, 3 deals together
- [Prospect Venture Partners](https://shizune.co/investors/profile/prospect-venture-partners) — VC Fund, 3 deals together
- [Venrock](https://shizune.co/investors/profile/venrock) — VC Fund, 3 deals together

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does CDIB BioScience Ventures invest in?

CDIB BioScience Ventures invests primarily in Biotechnology, Medical and Pharmaceutical startups, most often at Series C and Series A stage. Most of the 17 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did CDIB BioScience Ventures last invest?

The most recent investment recorded for CDIB BioScience Ventures closed in Jul 2008. Shizune tracks 17 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co